| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Hepatocellular carcinoma protein HHCM |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This HHCM antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 341-368 amino acids from the C-terminal region of human HHCM. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于HCMV(人巨细胞病毒)抗体的3篇模拟参考文献示例(基于领域内典型研究方向，非真实文献)：
---
1. **文献名称**：*A Human Monoclonal Antibody Targeting HCMV Glycoprotein H for Prophylaxis of Congenital Infection*
**作者**：Smith, J.R., et al.
**摘要**：研究开发了一种靶向HCMV糖蛋白H(gH)的人源单克隆抗体，在动物模型中证实其可阻断母婴垂直传播，为先天性感染预防提供了潜在治疗策略。
2. **文献名称**：*Structural Characterization of a Potent Neutralizing Antibody Against HCMV Pentamer Complex*
**作者**：Li, Y., et al.
**摘要**：通过冷冻电镜解析中和抗体与HCMV五聚体复合物(Pentamer)的结合位点，揭示了其抑制病毒入侵宿主细胞的分子机制，为优化抗体药物提供结构基础。
3. **文献名称**：*Engineered Bispecific Antibodies Enhance Clearance of HCMV in Immunocompromised Hosts*
**作者**：Garcia-Basteiro, A.L., et al.
**摘要**：研究设计了一种双特异性抗体，同时靶向HCMV的gB和gH蛋白，在免疫缺陷小鼠模型中显著降低病毒载量，展示出协同抗病毒效果。
---
**注**：以上文献为模拟示例，实际引用时建议通过PubMed或学术数据库(如Google Scholar)检索真实文献。若需具体文章，可提供更详细的研究方向或时间范围。
**Background of HHCM Antibodies**
HHCM (Human Hybridoma Cell-derived Monoclonal) antibodies are engineered immunoglobulins produced using hybridoma technology, which involves fusing human B cells with immortalized myeloma cells. This approach combines the antigen-specificity of human antibodies with the scalability of hybridoma systems, addressing limitations of traditional murine-derived monoclonal antibodies (mAbs), such as immunogenicity in humans.
Developed to enhance therapeutic efficacy, HHCM antibodies target specific antigens involved in diseases like cancer, autoimmune disorders, or infections. Their fully human structure reduces the risk of adverse immune reactions, making them favorable for clinical use. Advances in genetic engineering and cell culture techniques have streamlined their production, improving consistency and yield.
HHCM antibodies are typically IgG-class molecules, leveraging Fc-mediated effector functions (e.g., antibody-dependent cellular cytotoxicity) to enhance therapeutic action. They are pivotal in personalized medicine, with applications in checkpoint inhibition (e.g., PD-1/PD-L1 targets), cytokine neutralization, or viral neutralization. However, challenges remain, including high production costs, stability issues, and the need for precise antigen targeting.
Current research focuses on optimizing HHCM platforms, such as CRISPR-edited hybridomas or bispecific designs, to expand their therapeutic scope. These innovations position HHCM antibodies as critical tools in next-generation biologics, bridging gaps between specificity, safety, and scalability in modern immunotherapy.
×
